EXACT SCIENCES CORP (EXAS) Stock Price, Forecast & Analysis
NASDAQ:EXAS • US30063P1057
EXAS Key Statistics, Chart & Performance
The current stock price of EXAS is 103.325 USD. In the past month the price increased by 0.92%. In the past year, price increased by 118.2%.
EXAS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS is one of the better performing stocks in the market, outperforming 93.15% of all stocks.
EXAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EXAS. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability.
EXAS Financial Highlights
Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 81.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| Debt/Equity | 0.93 |
EXAS Forecast & Estimates
29 analysts have analysed EXAS and the average price target is 103.87 USD. This implies a price increase of 0.53% is expected in the next year compared to the current price of 103.325.
For the next year, analysts expect an EPS growth of 132.48% and a revenue growth 13.54% for EXAS
EXAS Ownership
EXAS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.65 | 403.74B | ||
| AMGN | AMGEN INC | 17.04 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.49 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.7 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.82 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.5 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.83 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EXAS
Company Profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Company Info
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719 US
CEO: Kevin T. Conroy
Employees: 6900
Phone: 16082845700
EXACT SCIENCES CORP / EXAS FAQ
What does EXAS do?
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
What is the stock price of EXACT SCIENCES CORP today?
The current stock price of EXAS is 103.325 USD. The price decreased by -0.12% in the last trading session.
Does EXACT SCIENCES CORP pay dividends?
EXAS does not pay a dividend.
What is the ChartMill rating of EXACT SCIENCES CORP stock?
EXAS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is EXACT SCIENCES CORP (EXAS) stock traded?
EXAS stock is listed on the Nasdaq exchange.
Can you provide the ownership details for EXAS stock?
You can find the ownership structure of EXACT SCIENCES CORP (EXAS) on the Ownership tab.
What is the outstanding short interest for EXACT SCIENCES CORP?
The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 3.56% of its float.